Verastem Inc (VSTM) Expected to Post Earnings of -$0.40 Per Share

Share on StockTwits

Wall Street analysts predict that Verastem Inc (NASDAQ:VSTM) will announce earnings per share (EPS) of ($0.40) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Verastem’s earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.34). Verastem reported earnings of ($0.43) per share during the same quarter last year, which suggests a positive year over year growth rate of 7%. The business is scheduled to announce its next quarterly earnings report on Tuesday, March 12th.

On average, analysts expect that Verastem will report full year earnings of ($1.40) per share for the current year, with EPS estimates ranging from ($1.52) to ($1.34). For the next financial year, analysts expect that the firm will post earnings of ($1.63) per share, with EPS estimates ranging from ($2.26) to ($0.85). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Verastem.

Verastem (NASDAQ:VSTM) last posted its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.14. The company had revenue of $15.51 million during the quarter.

Several research firms have recently issued reports on VSTM. BidaskClub raised Verastem from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Zacks Investment Research lowered Verastem from a “buy” rating to a “hold” rating in a research report on Saturday, January 5th. ValuEngine lowered Verastem from a “buy” rating to a “hold” rating in a research report on Monday, December 17th. Roth Capital set a $14.00 price target on Verastem and gave the stock a “buy” rating in a research report on Friday, November 9th. Finally, HC Wainwright set a $15.00 price target on Verastem and gave the stock a “buy” rating in a research report on Thursday, November 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $14.78.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC grew its holdings in shares of Verastem by 2,520.2% in the 2nd quarter. FMR LLC now owns 4,058,097 shares of the biopharmaceutical company’s stock worth $27,920,000 after acquiring an additional 3,903,218 shares during the period. BlackRock Inc. raised its position in Verastem by 240.6% in the second quarter. BlackRock Inc. now owns 3,542,912 shares of the biopharmaceutical company’s stock valued at $24,376,000 after purchasing an additional 2,502,853 shares during the period. Man Group plc acquired a new stake in shares of Verastem during the third quarter valued at about $5,419,000. Vanguard Group Inc grew its stake in Verastem by 20.5% in the third quarter. Vanguard Group Inc now owns 3,130,491 shares of the biopharmaceutical company’s stock worth $22,696,000 after purchasing an additional 532,484 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Verastem by 20.5% in the third quarter. Vanguard Group Inc. now owns 3,130,491 shares of the biopharmaceutical company’s stock worth $22,696,000 after purchasing an additional 532,484 shares in the last quarter. Institutional investors own 48.83% of the company’s stock.

VSTM opened at $3.72 on Friday. The company has a quick ratio of 2.97, a current ratio of 2.97 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $301.81 million, a PE ratio of -2.11 and a beta of 3.21. Verastem has a 1 year low of $2.77 and a 1 year high of $10.35.

Verastem Company Profile

Verastem, Inc, operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.

Read More: Understanding Stock Ratings

Get a free copy of the Zacks research report on Verastem (VSTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Village Farms International  Trading 20.4% Higher
Village Farms International Trading 20.4% Higher
Enablence Technologies  Trading Down 16.7%
Enablence Technologies Trading Down 16.7%
Q4 2019 EPS Estimates for Citizens Financial Group Inc  Lowered by Wedbush
Q4 2019 EPS Estimates for Citizens Financial Group Inc Lowered by Wedbush
Wynn Resorts, Limited Expected to Post FY2020 Earnings of $7.70 Per Share
Wynn Resorts, Limited Expected to Post FY2020 Earnings of $7.70 Per Share
UBS Group Reaffirms Buy Rating for Puma AG Rudolf Dassler Sport
UBS Group Reaffirms Buy Rating for Puma AG Rudolf Dassler Sport
Trevali Mining  Price Target Lowered to C$0.60 at National Bank Financial
Trevali Mining Price Target Lowered to C$0.60 at National Bank Financial


Leave a Reply

 
© 2006-2019 Zolmax.